• Natera disclosed clinical data already presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.
• The lung cancer study found Signatera MRD status following surgery helped identify patients more likely to relapse or die.
• Results supported use in both early post-surgical assessment and ongoing monitoring, pointing to a potential role in guiding adjuvant treatment decisions.
• Dataset covered 1,129 patients with resected stage 1-3 non-small cell lung cancer, spanning 2016 to 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260918220514) on September 18, 2026, and is solely responsible for the information contained therein.